Fraud & Abuse / Exclusion Screening
- OIG approved a drug manufacturer’s plan to pay for autoantibody testing that helps determine whether its drug for a rare lung disease may be appropriate for a patient. Under Advisory Opinion 26-20, the manufacturer would pay a third-party laboratory a fixed fee per test, and the test would be free to any patient with an abnormal CT scan, a qualifying symptom, and a health care professional’s attestation, regardless of income or insurance status. No patient or payor would be billed, the test is not reimbursable by Federal health care programs, and the manufacturer expects most results to be negative. OIG found the free test implicates the Federal anti-kickback statute and that no safe harbor applies, but it will not impose sanctions because sales representatives cannot promote the program, the manufacturer receives only aggregated, de-identified data, and ordering professionals are not paid or required to prescribe the drug. OIG also concluded the arrangement satisfies the Promotes Access to Care Exception to the Beneficiary Inducements CMP. The opinion will have no effect if FDA does not approve the drug. Source: OIG
- Federal regulations do not require hospitals to screen the Medicare Preclusion List, but a hospital can take on that obligation through its Medicare Advantage contracts or delegated arrangements. The Preclusion List payment restrictions apply to Medicare Advantage organizations and Part D sponsors, which may not pay for items, services, or drugs furnished, ordered, or prescribed by listed providers, and CMS makes the list available only to plans. An OIG-excluded provider goes on the Preclusion List as of the exclusion date, but a provider may be precluded without being excluded, so a clear LEIE search does not establish that a Medicare Advantage claim is payable. Since October 14, 2026, the CMS Administrator can exercise the Secretary’s permissive exclusion authority under section 1128(b) of the Social Security Act, so hospitals relying on the LEIE should confirm whether their screening vendor will capture CMS-imposed exclusions. Hospitals that discover an excluded individual face the 60-day overpayment rule and civil monetary penalty exposure, and OIG’s updated Self-Disclosure Protocol and a DOJ, OIG, and CMS False Claims Act self-disclosure pilot running through April 22, 2027 offer resolution paths. Source: Holland & Hart Health Law Blog
HIPAA & Data Privacy
- CHIME and 17 health systems urged HHS not to adopt HIPAA Privacy Rule changes that would bar providers from independently verifying whether patients authorized third-party apps to receive their protected health information. In a November 10 letter to HHS Secretary Robert F. Kennedy Jr., the groups said the final rule, which OCR is expected to release before year-end, may also treat Identity Assurance Level 2 credentials as sufficient for app requests even though those credentials do not confirm record matching or the scope of a patient’s authorization. The rule stems from a 2021 proposed update, and the coalition argues that a categorical ban on verification would depart from that proposal and violate the Administrative Procedure Act’s logical outgrowth doctrine without new notice-and-comment rulemaking. Signers include Cleveland Clinic, MedStar Health, Trinity Health, Sharp HealthCare, and AdventHealth. OCR said it does not comment on pending rulemaking. Source: BankInfoSecurity
- Six healthcare organizations agreed to settle class action lawsuits alleging that pixels and other tracking tools on their websites disclosed patients’ personal and health information to third parties such as Meta and Google. Dental Intelligence, Inc. agreed to a $5,750,000 fund over tracking code in its LocalMed scheduling software, Fertility Centers of Illinois to a $375,000 fund, and USC Arcadia Hospital to a $200,000 fund. Dallas-based Tenet Healthcare will pay $16 per claimant plus two years of a privacy protection service in a case over its websites and patient portals from 2017 to 2023, and Missouri Delta Medical Center will pay $20 per claimant. Prime Healthcare will pay $20 per claimant, stop using Google Analytics and Meta Pixel for five years, create a Web Governance Committee to audit its websites, and require business associate agreements from any tracking vendors. Each settlement has preliminary court approval, and all defendants deny wrongdoing. Source: The HIPAA Journal
GLP-1 Drugs
- FDA will require makers of GLP-1 receptor agonist drugs to add a label warning about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that can cause permanent vision loss. FDA’s meta-analysis of 126 trials covering more than 130,000 patients identified 15 probable NAION cases: 10 among GLP-1 patients, five among placebo patients, and none among patients on non-GLP-1 drugs. A separate FDA cohort study of type 2 diabetes patients from 2019 to 2024 found no increased risk compared with SGLT-2 inhibitors but an increased risk compared with DPP-4 inhibitors. The European Medicines Agency ordered similar labeling for semaglutide in 2025 and recommended stopping the drug if NAION is confirmed, while FDA advises providers to “consider discontinuing” it unless the benefits clearly outweigh the risk. The American Academy of Ophthalmology said FDA’s position is consistent with its May joint statement calling for shared decision-making, and noted that most studies to date have focused on semaglutide. Source: Ars Technica
- About 27 million U.S. adults, or 9.8%, used a GLP-1 medication in 2025, and 44% of them did not take it as prescribed, according to a CDC study. The study, published in the CDC’s Morbidity and Mortality Weekly Report, drew on survey responses from more than 8,000 adults collected in July and August 2025. Users reported skipping doses, delaying refills, and taking smaller doses than prescribed, and more than half of those who modified their use cited cost or availability. At least 23% of GLP-1 users took a compounded version, and 62% of compounded-drug users did not take the drug as prescribed, compared with 36% of brand-name users. A 2025 study of websites selling compounded GLP-1s found nearly 40% stated or implied the drugs were FDA-approved and nearly 80% used brand names in their advertising. Source: Ars Technica
Artificial Intelligence
- Healthcare AI vendor contracts built on generic software-as-a-service templates often omit five protections: zero data retention, a business associate agreement, breach notification deadlines, model change control, and allocation of clinical liability. A zero data retention clause should bar the vendor from storing patient data or using it to train models, and should extend to subprocessors, logs, backups, and human review. Any AI vendor that handles protected health information needs a signed business associate agreement before data flows, scoped to the minimum necessary data fields, and the contract should replace “commercially reasonable efforts” breach language with a deadline such as 24 to 72 hours after discovery. Because vendors retrain or silently update models, providers should require advance notice of material changes, a testing period, and the right to roll back, suspend, or terminate if an update fails acceptance criteria. Vendors routinely disclaim responsibility for output accuracy, so providers should negotiate validation commitments, indemnification for model or training data defects, and liability caps that do not undercut those protections. Source: Healthcare Law Insights
- Clinical trial sponsors that overstate their use of artificial intelligence face securities class actions and shareholder derivative suits regardless of whether the technology works. Under Rule 10b-5, courts treat generalized statements about AI’s “transformative potential” as nonactionable puffery, while specific claims, such as a model that “cuts screen-failure rates by 40%,” can be material if they cannot be substantiated. Derivative suits under Caremark duty-of-oversight theories can target directors who rely on AI without testing its reliability or who lack visibility into how AI is used in clinical development. Vulnerabilities include disclosures that emphasize AI benefits while omitting reliance on third-party vendors, no board reporting on AI risks, and vendor contracts that use generic software indemnification and warranty terms. The practice of exaggerating AI use to attract investors, known as “AI-washing,” has driven a rise in AI-related securities litigation that is spreading from the technology sector to life sciences. Source: Healthcare Law Insights
- Medtech companies that use AI in development must document human conception of their inventions, secure data and ownership rights, and identify a specific technical advance to obtain patent protection. The USPTO’s November 2025 revised guidance rescinded its earlier AI inventorship guidance and confirmed that ordinary inventorship standards apply, so AI is a tool and the inventor must be human. In Recentive Analytics, Inc. v. Fox Corp., the Federal Circuit rejected claims that applied generic machine learning to a new setting without a claimed technological improvement. Copyright requires human authorship, so a vendor’s promise that the customer owns AI-generated output does not create copyright, and pilot agreements with hospitals should state whether data may be used to train and commercialize a product. FDA reports more than 1,600 AI-enabled medical devices authorized as of September 2026, and 72% of physicians in an AMA survey reported using at least one AI use case. Source: Healthcare Law Insights
Texas Legislature
- Two bills filed to expand Medicaid eligibility on November 9, the first day of pre-filing for the 90th Texas Legislature. House Bill 101 would put Medicaid expansion to a statewide vote for all applicants for whom federal funds are available, and House Bill 102 would direct the executive commissioner of the Texas Health and Human Services Commission to “take all necessary actions” to expand the program administratively. Bucy has filed the same legislation in prior sessions and has also tried to expand Medicaid through budget amendments. Rep. Senfronia Thompson, who named health care as one of her priorities, said she has the votes to become the next House speaker. The Legislature convenes on January 12. Source: The Texan
Practice Operations
- A full appointment schedule does not guarantee profitability for a medical aesthetics practice, which depends on each treatment’s contribution margin, use of appointment time, and the effect of promotional discounts. Contribution margin, net treatment revenue minus variable costs such as product, consumables, and production-based provider pay, determines how much each service contributes toward rent, payroll, and other fixed expenses. In a hypothetical comparison of two $400 treatments, one contributed $100 more per visit, but the other produced more contribution per scheduled hour because it took 30 minutes instead of 60. Discounting a $400 treatment to $350 for 40 patients who would have paid full price gives up $2,000 in revenue, which takes about six new appointments to recover on a gross revenue basis. Evaluating core services by revenue, variable cost, contribution per visit and per hour, and the effect of discounts gives a practice a basis for pricing, scheduling, and promotion decisions. Source: VMG Health
